Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Strati

Showing results (61-70 of 139) with videos related to

Pageof 14
Sort By:
Nature Cancer|January 6, 2026
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trialPaolo Strati, Lori Leslie, Parveen Shiraz, et al.
Blood|September 21, 2019
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapyPhilip A Thompson, Jaya Srivastava, Christine Peterson, et al.
Blood Cancer Journal|May 6, 2020
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-upHui Zhou, Zijun Y Xu-Monette, Ling Xiao, et al.
Haematologica|June 20, 2015
Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experiencePaolo Strati, Samih H Nasr, Nelson Leung, et al.
Cancer|April 16, 2026
Assessing patient perspectives on enrollment in lymphoma clinical trialsNeha Akkad, Minxing Chen, Sophia Nguyen, et al.
Journal for Immunotherapy of Cancer|October 9, 2025
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapyPaolo Strati, Amanda Brandt, Anath C Lionel, et al.
Clinical and Translational Radiation Oncology|May 23, 2022
Second malignancies in patients with Hodgkin's Lymphoma: Half a century of experienceBouthaina Shbib Dabaja, David Boyce-Fappiano, Wenli Dong, et al.
Blood Cancer Journal|August 28, 2020
Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different featuresWen Shuai, Pei Lin, Paolo Strati, et al.
The Lancet. Haematology|July 3, 2025
Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 studyPaolo Strati, Januario Castro, Aaron Goodman, et al.
Blood Advances|March 3, 2022
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapySushanth Gouni, Allison C Rosenthal, Jennifer L Crombie, et al.
Pageof 14

Showing results (61-70 of 139) with videos related to

Sort By:
Pageof 14
Nature Cancer|January 6, 2026
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trialPaolo Strati, Lori Leslie, Parveen Shiraz, et al.
Blood|September 21, 2019
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapyPhilip A Thompson, Jaya Srivastava, Christine Peterson, et al.
Blood Cancer Journal|May 6, 2020
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-upHui Zhou, Zijun Y Xu-Monette, Ling Xiao, et al.
Haematologica|June 20, 2015
Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experiencePaolo Strati, Samih H Nasr, Nelson Leung, et al.
Cancer|April 16, 2026
Assessing patient perspectives on enrollment in lymphoma clinical trialsNeha Akkad, Minxing Chen, Sophia Nguyen, et al.
Journal for Immunotherapy of Cancer|October 9, 2025
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapyPaolo Strati, Amanda Brandt, Anath C Lionel, et al.
Clinical and Translational Radiation Oncology|May 23, 2022
Second malignancies in patients with Hodgkin's Lymphoma: Half a century of experienceBouthaina Shbib Dabaja, David Boyce-Fappiano, Wenli Dong, et al.
Blood Cancer Journal|August 28, 2020
Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different featuresWen Shuai, Pei Lin, Paolo Strati, et al.
The Lancet. Haematology|July 3, 2025
Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 studyPaolo Strati, Januario Castro, Aaron Goodman, et al.
Blood Advances|March 3, 2022
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapySushanth Gouni, Allison C Rosenthal, Jennifer L Crombie, et al.
Pageof 14